News Release

October 25, 2019

Neovasc to Announce Third Quarter 2019 Financial Results on Thursday, November 7, 2019

®NASDAQ, TSX: NVCN

VANCOUVER, Oct. 25, 2019Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended September 30, 2019 and host a conference call at 4:30 PM Eastern Time on Thursday, November 7, 2019.

 Conference Call & Webcast

 Thursday, November 7, 2019 @ 4:30 pm Eastern Time

Domestic:                  888-220-8474
International:            323-794-2588
Conference ID:         5350680
Webcast:                   http://public.viavid.com/index.php?id=136842

 

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

Investors:
Mike Cavanaugh
Phone: +1.646.677.1838
Mike.Cavanaugh@westwicke.com
Westwicke, an ICR Company

Media:
Sean Leous
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Westwicke, an ICR Company

 

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

SOURCE Neovasc Inc.